Madrigal Pharmaceuticals Inc (MDGL)
R&D Expense Growth
-16.11%
Quarterly · Period ending:
MDGL R&D Expense Growth
Latest reported-16.11%period ending
Latest reported-16.11%period ending
MDGL Quarterly R&D Growth (QoQ) (0.00% → -16.11%)
Latest values, visible window
High-resolution chart · PNG
MDGL r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| -16.1134% | |
| -6.516% | |
| -33.1808% | |
| 221.747% | |
| 22.4328% | |
| 72.224% | |
| -62.6895% | |
| -3.3042% | |
| -0.2049% | |
| 0.8451% | |
| -0.4383% | |
| 3.4196% | |
| 10.3791% | |
| -12.1399% | |
| 3.6194% | |
| 16.7046% | |
| 22.0535% | |
| -9.3781% | |
| -3.6156% | |
| 6.2771% | |
| 12.8075% | |
| -14.3349% | |
| 0.2571% | |
| 19.2535% | |
| 33.7964% | |
| 34.0827% | |
| 28.0917% | |
| 24.7082% | |
| 26.0325% | |
| 39.4769% | |
| 42.8272% | |
| 21.5698% | |
| -1.7122% | |
| -20.1781% | |
| -2.5441% | |
| -1.966% | |
| 55.6164% | |
| -20.7096% | |
| -29.2249% | |
| 7,677.6699% | |
| -103.0232% | |
| -52.981% | |
| -49.7259% | |
| -11.9924% | |
| 1.205% | |
| 3.3795% | |
| -3.4242% | |
| -13.608% | |
| 6.6997% | |
| -12.0014% | |
| 13.3802% | |
| -1.4153% | |
| 9.1331% | |
| 14.1384% | |
| 22.209% | |
| 4.3637% | |
| -6.7462% | |
| 11.1152% | |
| 1.0046% | |
| 3.2063% | |
| 10.3964% | |
| 0.963% | |
| -15.2136% | |
| 13.7799% | |
| -4.973% | |
| 10.4191% | |
| 1.6402% | |
| -10.0416% | |
| -55.3956% | |
| -1.7021% | |
| -4.2689% | |
| 31.1635% | |
| 13.5728% | |
| 21.1189% | |
| 15.5259% | |
| -15.2134% | |
| -5.4521% | |
| 36.7591% | |
| -20.9906% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| -100% | |
| 0% | |
| 0% |